Reuters
10 Jun 2026, 12:44 UTC · 2h ago
Organon wins US approval to widen use of arthritis biosimilar drug
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 1 mover · tap to explore
Reuters
10 Jun 2026, 12:44 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 1 mover · tap to explore
What the story claims
1 claim · each scored for market impact
The FDA approved the expanded use of Organon's Actemra biosimilar to treat life-threatening immune reactions in cancer patients and severe COVID-19. — Expanded indications for a biosimilar increase the total addressable market and revenue potential for Organon.
+0.60Which stocks this story touches
The company received FDA approval for expanded use of its arthritis drug.
The approval of a biosimilar to its drug Actemra increases competition and may erode market share.
Continue reading
6 related stories
[mutual] Organon produces a biosimilar version of Roche's Actemra, competing in the same therapeutic market.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
ROG showed up in this week’s NIS Momentum screen.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
GlobeNewsWire
1h ago
